\n
\n
![\"EarthSnap\"\/](\"https:\/\/www.newsbeep.com\/il\/wp-content\/uploads\/2025\/12\/1766790432_598_earthsnap-banner-news.webp.webp\")
\n<\/a><\/p>\n
Across 17 placebo-controlled trials<\/a>, 20,342 participants with mild memory problems or mild dementia received one of seven drugs or placebo.<\/p>\n Working through that evidence, Francesco Nonino at the IRCCS Institute of Neurological Sciences of Bologna, (ISNB<\/a>) found effects too small for patients to feel.<\/p>\n That pattern held even though the review included the newer medicines already in U.S. clinics alongside older drugs that had failed.<\/p>\n Even so, the finding stops short of settling what any single drug can do, which is why the argument widens from here.<\/p>\n Significance of amyloid<\/p>\n These drugs target amyloid, sticky protein buildup linked to Alzheimer\u2019s, because researchers long suspected it helped drive the disease.<\/p>\n Each antibody latches onto that protein and marks it for removal, engaging the brain\u2019s cleanup cells to clear plaques.<\/p>\n Later, lecanemab<\/a>, a drug that targets and removes amyloid buildup in the brain, and donanemab<\/a>, a similar treatment designed to clear those protein deposits, each showed enough slowing to win U.S. approval in 2023 and 2024.<\/p>\n That history explains why a pooled verdict feels harsher than the story many patients heard when those approvals arrived.<\/p>\n Brain swelling and bleeding risks<\/p>\n Safety is where the review lands hardest, because these drugs increased amyloid-related imaging abnormalities, scan-detected swelling or bleeding in the brain.<\/p>\n When antibodies strip amyloid<\/a> from blood vessel walls as well as plaques, fragile vessels can leak fluid or small amounts of blood.<\/p>\n At 18 months, the pooled review found 107 more cases of swelling per 1,000 treated people than placebo.<\/p>\n Most episodes seen on scans caused no obvious symptoms, but the authors said inconsistent reporting leaves the long-term consequences uncertain.<\/p>\n Measuring meaningful change<\/p>\n The sharpest point in the review is not that scores barely moved, but that the movement was likely negligible.<\/p>\n Public remarks<\/a> from the review team made one issue unmistakable: small score changes are not always felt in daily life.<\/p>\n \u201cUnfortunately, the evidence suggests that these drugs make no meaningful difference to patients,\u201d said Nonino.<\/p>\n Whether that definition of meaningful is too strict sits at the center of the backlash from some clinicians.<\/p>\n Controversy behind the conclusions<\/p>\n Critics say the pooled result blurs older failed antibodies with the two drugs now used in U.S. memory clinics.<\/p>\n By combining one lecanemab trial and one donanemab trial with many earlier failed drugs, the review ends up judging the whole group rather each singular drug.<\/p>\n \u201cExisting approved drugs offer some benefit for some patients,\u201d said Edo Richard, professor of neurology at Radboud University Medical Center<\/a>.<\/p>\n Gaps in long-term data<\/p>\n The review also points to a basic problem in the evidence, because most trials lasted only about 18 months.<\/p>\n Alzheimer\u2019s progresses slowly, so a short follow-up can miss later benefit or later harm.<\/p>\n Reporting also broke down on symptoms, making it clearer to the public what scans showed versus what patients felt.<\/p>\n That gap weakens both camps, because supporters and skeptics are still arguing over side effects that were not described well enough.<\/p>\n Cost and complexity of treatment<\/p>\n Even modest benefits would come with heavy logistics, because these medicines are given by infusion and demand repeated brain scans.<\/p>\n Doctors must confirm amyloid before treatment and keep watching for these changes, which means more appointments, staff time, and scanner access.<\/p>\n That burden hits unevenly, since trial populations were mostly homogenous and the monitoring structure favored health systems with vast resources.<\/p>\n A drug can be approved and still inaccessible to many families, hospitals, and public insurers.<\/p>\n Moving beyond amyloid<\/p>\n The review<\/a> does not say Alzheimer\u2019s is untreatable, only that amyloid removal alone has not delivered what patients need.<\/p>\n That conclusion focuses on other brain targets, including inflammation, the immune activity that can damage brain tissue.<\/p>\n Nonino said the field now needs other targets, not just better ways to remove the same protein.<\/p>\n Future drugs may still hit amyloid, but many researchers now expect combinations that tackle several processes at once.<\/p>\n Real-world treatment tradeoffs<\/p>\n None of this turns treatment choices into a simple yes or no, especially for people already taking these drugs.<\/p>\n Current patients<\/a> face tradeoffs between small possible slowing, known monitoring demands, and a real chance of swelling or bleeding.<\/p>\n For some families, a modest delay still matters, while others may decide the clinic time and possible uncertainty.<\/p>\n That is why the most important lesson from this review may be honesty, not panic, during informed consent.<\/p>\n A narrow view of current drugs<\/p>\n The evidence now paints a narrow and uncomfortable picture: amyloid-clearing drugs can change brain biology without clearly changing life in ways patients notice.<\/p>\n Researchers will keep testing longer courses and new combinations, but clinicians already must explain that lower plaque counts are not better days.<\/p>\n The study is published in the journal Cochrane Database of Systematic Reviews<\/a>.<\/p>\n \u2014\u2013<\/p>\n Like what you read?\u00a0Subscribe to our newsletter<\/a>\u00a0for engaging articles, exclusive content, and the latest updates.<\/p>\n Check us out on\u00a0EarthSnap<\/a>, a free app brought to you by\u00a0Eric Ralls<\/a>\u00a0and Earth.com.<\/p>\n \u2014\u2013<\/p>\n","protected":false},"excerpt":{"rendered":"A new review has found that drugs designed to clear amyloid, a protein that builds up in the…\n","protected":false},"author":2,"featured_media":400912,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[163,85,46],"class_list":{"0":"post-400911","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-health","8":"tag-health","9":"tag-il","10":"tag-israel"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/400911","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/comments?post=400911"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/400911\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media\/400912"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media?parent=400911"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/categories?post=400911"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/tags?post=400911"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}